Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naive & experienced metastatic melanoma patients

被引：7
|
作者：
Leung, Abraham C. F.
Kummar, Shivaani
Agarwala, Sanjiv S.
Nemunaitis, John J.
Gonzalez, Rene
Drabick, Joseph J.
Schmidt, Emmett V.
Chartash, Elliot
Xing, Biao
Currie, Graeme
Janssen, Robert
Ribas, Antoni
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.9550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9550
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.
    Janku, Filip
    Hamilton, Erika P.
    Mathews, Cara Amanda
    Chu, Christina
    Diamond, Jennifer Robinson
    Hays, John L.
    Arend, Rebecca Christian
    Cristofanilli, Massimo
    Jewell, Andrea
    Reichmann, William
    Kuida, Keisuke
    Achour, Haroun
    Ruiz-Soto, Rodrigo
    Richardson, Debra L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] PHASE 1B DOSE-ESCALATION STUDY OF SD-101, A NOVEL THERAPEUTIC TLR-9 AGONIST, IN TREATMENT-NAIVE CHRONIC HEPATITIS C PATIENTS
    Cianciara, J.
    Martin, J. T.
    Spellman, M. C.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S126 - S126
  • [23] COMBINATION OF FECAL MICROBIOTA TRANSPLANTATION FROM HEALTHY DONORS WITH ANTI-PD1 IMMUNOTHERAPY IN TREATMENT-NAIVE ADVANCED OR METASTATIC MELANOMA PATIENTS
    Maleki, Saman
    Lenehan, John
    Burton, Jeremy
    Silverman, Michael
    Parvathy, Seema Nair
    El-Hajjar, Mikal
    Krishnamoorthy, Mithunah
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A11 - A12
  • [24] A phase 1b multicenter study of anti-TIM3 (S095018/Sym023) in combination with anti-PD1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer
    Ghiringhelli, Francois
    Kim, Richard
    Macarulla, Teresa
    Moreno, Irene
    Razak, Albiruni
    Rodon, Jordi
    Liao, Chih-Yi
    Marron, Thomas
    Raimbourg, Judith
    Kaplon, Helene
    Geromini, Julia
    Harouki, Najah
    Rodrigues, Christelle
    Darcel, Pauline
    Skartved, Niels Jorgen
    Hald, Rikke
    Lopez-Ravnborg, Daleen
    He, Peng
    Ianopoulos, Xenophon
    Askoxylakis, Vasileios
    Lakhani, Nehal J.
    Davis, Sarah
    Mahipal, Amit
    CANCER RESEARCH, 2024, 84 (07)
  • [25] A phase II study of anti-PD1 monoclonal antibody (Nivolumab) administered in combination with anti-LAG3 monoclonal antibody (Relatlimab) in patients with metastatic melanoma naive to prior immunotherapy in the metastatic setting.
    Rohatgi, Anjali
    Massa, Ryan Campbell
    Gooding, William E.
    Bruno, Tullia C.
    Vignali, Dario
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Neoantigen Identification and Response to Adoptive Cell Transfer in Anti-PD-1 Naive and Experienced Patients with Metastatic Melanoma
    Levi, Shoshana T.
    Copeland, Amy R.
    Nah, Shirley
    Crystal, Jessica S.
    Ivey, Gabriel D.
    Lalani, Almin
    Jafferji, Mohammad
    White, Bradley S.
    Parikh, Neilesh B.
    Leko, Vid
    Krishna, Sri
    Lowery, Frank
    Prickett, Todd D.
    Gartner, Jared J.
    Jia, Li
    Li, Yong F.
    Sachs, Abraham
    Sindiri, Sivasish
    Robinson, Welles
    Gasmi, Billel
    Yang, James C.
    Goff, Stephanie L.
    Rosenberg, Steven A.
    Robbins, Paul F.
    CLINICAL CANCER RESEARCH, 2022, 28 (14) : 3042 - 3052
  • [27] A phase 1b, open-label, dose escalation and expansion study of demcizumab plus pembrolizumab in patients with locally advanced or metastatic solid tumors
    Johnson, Melissa
    Rasco, Drew
    Schneider, Brian
    Shu, Catherine
    Jotte, Robert
    Parmer, Hema
    Stagg, Robert
    Lopez, Juanita
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [28] Initial results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody ®) in combination with pembrolizumab (an anti-PD-1 antibody) in patients with advanced/metastatic solid tumors
    Li, Daneng
    Sharma, Sunil
    She, Kristine
    Li, Wenda
    Li, Ai
    Zheng, Songmao
    Liu, Guizhong
    Ndukwo, Ogon
    Hu-Lowe, Dana
    Chisamore, Michael
    Luo, Peter
    Zha, Jiping
    Patel, Manish R.
    CANCER RESEARCH, 2023, 83 (08)
  • [29] CAPRA: A Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients
    Silk, Ann
    Kaufman, Howard
    Gabrail, Nashat
    Mehnert, Janice
    Bryan, Jennifer
    Norrell, Jacqueline
    Haider, Azra
    Medina, Daniel
    Bommareddy, Praveen
    Shafren, Darren
    Grose, Mark
    Zloza, Andrew
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [30] Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study
    Timmerman, John
    Lavie, David
    Johnson, Nathalie A.
    Avigdor, Abraham
    Borchmann, Peter
    Andreadis, Charalambos
    Bazargan, Ali
    Gregory, Gareth P.
    Keane, Colm
    Tzoran, Inna
    Vucinic, Vladan
    Zinzani, Pier Luigi
    West, Rachel Marceau
    Pillai, Pallavi
    Marinello, Patricia
    Herrera, Alex F.
    BLOOD, 2023, 142
12345